Aptose Biosciences Inc (APTO)

[Decatsmeow]

Aptose Biosciences. Inc. Forward-Looking Analysis

There is much competition for Aptose to fight against in the “finding the cure for cancer” market. From a business perspective, having a drug that cures cancer will practically print money for them. For example, some treatments for cancer can cost from $3000 too much more. These drugs, depending on their effectiveness, can create profits in the $1 Billion+ region. Because of this, many institutions are putting funds into finding the cure for various forms of cancer. This market is contently changing with new discoveries being frequently made. From a business standpoint, you need to make a drug that is more efficient, more effective, and more cost-effective to sell to the public. Simply, if you make the better drug and sell it for cheaper, your business will gain the market.


Looking at Aptoses’ income statement, they have a running loss with $0 in revenue. For the first quarter of 2017, the company had a net loss of ~$4,355,000. Also, over the course of the last year, the company has had a net loss of ~$17,910,000. Unless the company can create and sell one of their cures, Aptose will continue to run at a loss. If the company was to sell one of their cures, it comes down to how effective and efficient the drug is. These medicines would help it penetrate a full cancer treatments market. There is the possibility that the drugs and treatments could sell very well, but there is serious doubt that such an event will happen.

Aptoses’ balance statement shows that it has ~11,958,000 in on hand cash Q1 2017. From what we were able to find, the company is gaining on-hand cash from selling company shares to investors. In total, Aptose has a total of ~$12,676,000 in assets for Q1 2017. For accounts payable, Aptose has ~$2,340,000 in current liabilities. For shareholders equity, investors of Aptose have ~$235,869,000 in shares. The accumulated deficit for investors is ~$247,877,000.

Read More Here